Eli Lilly: The Next $1 Trillion Market Cap Stock?

Core Insights - Eli Lilly reported a 36% increase in revenue, primarily driven by Mounjaro, Zepbound, and Verzenio, with EPS rising 68% year-on-year, surpassing analysts' estimates by 42% [1] - The company raised its full-year revenue guidance by $3 billion and highlighted significant progress in its drug pipeline, including approvals for Kisunla and Jaypirca, and positive clinical trial results for tirzepatide [1] Financial Performance - Eli Lilly's current market cap stands at $535 billion, with a potential to reach $1 trillion if the stock price doubles [3] - The GLP-1 market is projected to grow over 20% annually, reaching $133 billion by 2030, with Eli Lilly holding a dominant position due to Mounjaro [3] - Revenue is expected to grow by 23% this year, and if the company maintains a 20% growth rate, it could reach $100 billion in three to four years [4] Growth Projections - Analysts estimate Eli Lilly's EPS to grow at an annual rate of 33.3% over the next three to five years, indicating strong growth potential [5] - Current sales estimates for Eli Lilly show a projected revenue of $42.99 billion for the current year and $53.05 billion for the next year, with year-over-year growth estimates of 25.97% and 23.41% respectively [8] Competitive Landscape - Eli Lilly's competitors, Novo Nordisk and Hims & Hers Health, are also experiencing significant growth, with Novo Nordisk reporting a 24% increase in sales and Hims & Hers Health achieving a 52% year-on-year revenue increase [6][7] - The GLP-1 market trend is substantial, and while Eli Lilly is a strong candidate for investment, competitors also present appealing opportunities [11]